Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-10-18
1996-08-13
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 43, 514294, 514323, 514414, 514429, 540479, 540480, 540586, 540602, 546 94, 546201, 548430, 548455, 548466, 548468, 536 221, 536 286, A61K 31435, A61K 31445, C07D46300, C07D40314
Patent
active
055456367
ABSTRACT:
The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
REFERENCES:
patent: 4785085 (1988-11-01), Kaneko et al.
patent: 4808613 (1989-02-01), Kaneko et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5057614 (1991-10-01), Davis et al.
patent: 5292747 (1994-03-01), Davis et al.
patent: 5380746 (1995-01-01), Barth
Derwent Abstract 90-132947/18; (1988)-DE-835842.
Derwent Abstract 92-274042/33;(1990) 90JP-314628.
Meier, et al., Tetrahedron Letters, 34:33, 5277-5280.
Wilkinson, et al., Bichem. J., 294, 335-337 (1993).
Bit, et al., J. Med. Chem., 36, 21-29 (1993).
Martiny-Baron, et al., The Journal of Biological Chemistry, 268:13, 9194-9197 (1993).
Krakowiak, et al, Synlett, 611-620, (Sep. 1993).
Mulgueen, et al., Agents Actions, 37, 85-89 (1992).
Davis, et al., J. Med. Chem., 35, 177-184 (1992).
Davis, et al., J. Med. Chem., 35, 994-1001 (1992).
Toullec, et al., The Journal of Biological Chemistry, 266:24, 15771-15781 (1991).
Nixon, et al., Drugs Exptl. Clin. Res., 17:8, 389-393 (1991).
Davis, et al., Tetrahedron Letters, 31:36, 5201-5204 (1990).
Brenner, et al., Tetrahedron Letters, 44:10, 2887-2892 (1988).
Joyce, et al., The Journal of Organic Chemistry, 52:7, 1177-1186 (1987).
Buchdunger, et al., Proc. Natl. Acad. Sci. USA, 91, 2334-2338 (Mar. 1994).
Kobayashi, et al., The American Physiological Society, 0363-6135, H1214-H1220 (1994).
Felsenstein, et al., Neuroscience Letters, 174 173-176 (1994).
Demaerschalck, et al., Biochimica et Biophysica Acta, 1181 214-218 (1993).
Shimohama, et al., Neurology, 43 1407-1413 (1993).
Heath, Jr. William F.
McDonald, III John H.
Paal Michael
R uhter Gerd
Schotten Theo
Boone David E.
Caltrider Steven P.
Chang Ceila
Eli Lilly and Company
LandOfFree
Protein kinase C inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase C inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1048050